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PARKINSON’S DISEASE DRUG THERAPIES: MEDICATION COMPLIANCE 
AND PERSISTENCE
Tarrants ML1, Denarie MF2, Karabas T1, Castelli-Haley J1, Millard J2, Zhang D2
1Teva Neuroscience, Kansas City, MO, USA, 2IMS Health, Plymouth Meeting, PA, USA
OBJECTIVES: To examine compliance and persistence by drug therapy for 
Parkinson’s disease (PD) patients. Previous studies found strong associations between 
the worsening of PD symptoms and suboptimal compliance. METHODS: Using the 
IMS Longitudinal Prescription database that contains over 50% of all retail prescrip-
tions and 150 million patients, a retrospective analysis was done of PD patients 
receiving a new PD drug between March-May 2007. A patient receiving a new PD 
drug included initiating PD therapy, addition of adjunctive PD therapy or PD drug 
switch. Patients were further divided into naïve to PD therapy (NT) and prior PD 
therapy (PT), inclusive of adjunctive use and switches. Patients were active in the 
database for a 12 month observation period and a 12 month look-back period. 
Compliance was measured by medication possession ratio (MPR). Persistence was 
measured by duration of uninterrupted therapy. RESULTS: A total of 29,682 PD 
patients receiving a new PD drug were identiﬁed and analyzed. Sixty-six percent were 
NT, 34% were PT. 41% of the NT prescriptions were written by neurologists, 29% 
by primary care physicians and 17% by internists. Overall 54% of all PD patients 
had compliance rates over 80%. Compliance rates were higher for PT patients than 
NT patients. Rasagiline had signiﬁcantly higher average MPR (80.8) than any other 
product, followed by ropinirole (76.8), carbidopa/levodopa/entacapone (74.9), selegi-
line (73.9), COMT (73.6), pramipexole (72.9) and carbidopa/levodopa (71.8). The 
median number of persistent days for NT was highest for rasagiline (82) followed by 
carbidopa/levodopa (69), ropinirole (63), pramipexole (59), carbidopa/levodopa/enta-
capone (53), selegiline (47) and COMT (34). CONCLUSIONS: In this study rasagiline 
was associated with the highest rates of compliance and persistence. Favorable toler-
ability proﬁle, symptomatic beneﬁt and once daily administration of rasagiline may 
contribute to these results. Further analysis will be necessary to verify subsequent 
improvement on clinical and economic outcomes.
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MEDICATION ADHERENCE WITH DISEASE MODIFYING TREATMENTS 
FOR MULTIPLE SCLEROSIS: FINDINGS FROM A US NATIONAL 
DATABASE OF EMPLOYEES
Brook RA1, Rajagopalan K2, Kleinman NL3, Beren IA4
1The JeSTARx Group, Newfoundland, NJ, USA, 2Biogen Idec Pharmaceuticals, Cambridge, 
MA, USA, 3HCMS Group, Paso Robles, CA, USA, 4HCMS Group, Cheyenne, WY, USA
OBJECTIVES: Medication adherence in chronic diseases like multiple sclerosis plays 
an important role in predicting long term outcomes. Data on medication adherence 
with disease modifying treatments (DMTs) are available for the treatment of multiple 
sclerosis (MS), However, such adherence comparisons between employees on different 
DMTs are not available. The Study Objective was to compare adherence among 
employees treated with DMTs for MS. METHODS: A health care claims database of 
US employees from 2001–2008 was used to identify patients with MS. Patients with 
two or more DMT prescriptions or 1 DMT prescription with a MS diagnosis [ICD-9 
 340.X]). Employees continuously employed and with health plan coverage for one 
year following DMT initialization were eligible. Two measures were used in estimating 
adherence after DMT initialization: a) annual persistence, deﬁned as the sum of days 
with a medication supply prior to any 30-day gap in supply and b) medication pos-
session ratio (MPR), deﬁned as the number of days with a medication supply divided 
by 365 days. Wilcoxon tests on Kaplan Meier survival data and t-tests were used 
to compare persistence and MPR, respectively, between DMT groups. RESULTS: 
Overall, 358 employees [179  Avonex (Interferon [IFN]-B1a-IM); 63  Betaseron 
(IFN-B1b); 96  Copaxone (glatiramer acetate); 20  Rebif (IFN-B1a-SC)] were eligible 
for analysis. No signiﬁcant differences in age, gender, and certain job-related variables 
existed between cohorts. Persistence was signiﬁcantly better for Avonex than Betase-
ron (P  0.0096) and Copaxone (P  0.0004) and non-signiﬁcantly better than Rebif 
(P  0.1207). Also, a greater proportion of Avonex employees were persistent at 1-year 
(60.89%) than Betaseron (42.86%, P  0.0131), Copaxone (42.71%, P  0.0039), 
and Rebif (45.00%, P  0.1700). Avonex also had the highest MPR (0.782) and was 
signiﬁcantly higher than Copaxone (MPR  0.698, P  0.0160) and non-signiﬁcantly 
higher than Betaseron (MPR  0.705, P  0.0576) and Rebif (MPR  0.761, 
P  0.7347). CONCLUSIONS: Among employees treated with Avonex, Betaseron, 
Copaxone and Rebif for MS, Avonex patients had signiﬁcantly greater medication 
adherence.
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HEALTH UTILITY SCORES ASSOCIATED WITH A HYPOTHETICAL 
MODERATE ALZHEIMER’S DISEASE HEALTH STATE: A CANADIAN 
SURVEY OF THE GENERAL PUBLIC
Tarride JE, Oremus M, Clayton N, Raina P
McMaster University, Hamilton, ON, Canada
OBJECTIVES: 1) To elicit health utility scores for moderate Alzheimer’s disease (AD) 
using the Canadian general public; 2) to compare utility scores for Canadians’ self-
assessed health status with utility scores for health status deﬁned as moderate AD; 3) 
to measure awareness of AD; and 4) to determine factors that inﬂuence utility scores. 
METHODS: Five-hundred Canadians were chosen randomly to participate in a 13-
minute telephone interview. The sample was national in scope and stratiﬁed by 
income. The EQ-5D was administered to measure utility for respondents’ current 
health status (i.e., no AD). After describing moderate AD, respondents were asked to 
answer the EQ-5D again, this time imagining they had moderate AD. AD awareness 
was measured with the Alzheimer’s Disease Knowledge Test (ADKT). Respondents 
were also asked about socio-demographics and whether they knew someone with AD. 
OLS regressions were conducted to identify determinants of EQ-5D utility scores. 
RESULTS: The mean age of respondents was 51 years, 61% were female, and 42% 
knew someone with AD (e.g., family member). Mean ADKT score was 3.4 (SD: 1.1) 
out of 5 (higher scores indicate better knowledge of AD). Respondents’ mean EQ-5D 
score for their current health status was 0.857 (SD: 0.15). Mean EQ-5D score for a 
hypothetical, moderate AD health status was 0.638 (SD: .20), a utility decrement of 
0.22. For the VAS component of the EQ-5D, scores were higher for the current health 
status (79.16 versus 57.66). Age and income were signiﬁcant explanatory variables 
for current health status utilities, but only age was signiﬁcant in the determination of 
the utility score under the assumption of moderate AD. Gender, knowledge of 
someone with AD, or AD awareness scores had no impact. CONCLUSIONS: When 
measured by the EQ-5D, Canadians would expect to assign a lower utility to their 
health status when they have moderate AD.
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NEW QUALITY OF LIFE (QOL) DATA ON UK PATIENTS WITH 
REFRACTORY NEUROPATHIC PAIN
Lister S1, Gordon JP2, McEwan P2
1Pﬁzer Limited, Tadworth, Surrey, UK, 2CHKS Health Economics Unit, Cardiff, UK
OBJECTIVES: This study gathered new evidence on the relationship between pain 
and quality of life, in UK patients with refractory neuropathic pain. METHODS: 
Patients with neuropathic pain, attending a UK pain management clinic during 2008, 
were surveyed by post. The EQ-5D was included in the survey, so the severity of 
patients’ pain could be linked to their QOL. Additional data collected included dura-
tion of pain, co-morbidities, and pain-related prescriptions. RESULTS: 815 surveys 
were posted; 313 surveys (38%) were returned. Of the 313 responders, 144 suffered 
from refractory neuropathic pain (a duration of neuropathic pain of at least ﬁve years, 
and patient currently taking at least two pain-related medicines.) Refractory patients’ 
characteristics (n  144): mean age 59 years; two-thirds female; one-ﬁfth unemployed; 
mean duration of pain 26 years; and mean (current) pain score 5.7. Quality of life 
scores ranged from 0.53 (no pain) to 0.04 (highest level of pain). For refractory 
patients, QOL values were considerably lower for all severities of pain, ranging from 
0.43 to 0.06. Differences in utility were not attributable to major demographic and 
clinical factors (e.g., age, sex, diagnosis of diabetes or shingles), but to differences in 
pain severity. CONCLUSIONS: A negative relationship was observed between pain 
severity and quality of life. Patients currently experiencing no pain reported a quality 
of life of only 0.53. Refractory patients were generally associated with a longer dura-
tion of pain and lower quality of life compared to the total patient cohort. All patients 
with neuropathic pain experience a poorer quality of life than patients in perfect 
health, worsening as pain becomes more severe. Patients with refractory neuropathic 
pain experience a yet worse quality of life. This highlights the substantial suffering of 
patients with refractory neuropathic pain.
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LINGUISTIC VALIDATION OF THE MULTIPLE SCLEROSIS IMPACT 
SCALE (MSIS-29) FOR USE IN 29 LANGUAGES
Osmani D1, Rajagopalan K2, Hobart J3
1MAPI Institute, Lyon, France, 2Biogen Idec, WELLESLEY, MA, USA, 3Peninsula College of 
Medicine & Dentistry, Plymouth, UK
OBJECTIVES: The multiple sclerosis impact scale (MSIS-29) developed in UK English 
is a reliable, valid, and sensitive 29-item measure of the physical and psychological 
impact of MS on patients’ day-to-day life. For an international study, the MSIS-29 
had to be translated into 29 languages for 19 countries. A thorough methodology was 
required to ensure conceptual equivalence and cultural relevance across languages. 
METHODS: A standardized methodology was conducted by specialists in each target 
country: 1) deﬁnition of original concepts in collaboration with the developer; 2) two 
forward translations by native target-language speakers; 3) comparison and reconcili-
ation of the translations; 4) back translation by a native English speaker; 5) compari-
son of original and back translation; 6) comprehension test on 5 patients, native 
target-language speakers and suffering from multiple sclerosis and; 7) international 
harmonization. RESULTS: Two main challenges emerged. On the conceptual level, 
the English original made extensive use of synonyms to cover one concept which was 
not possible in most target languages and appropriate solutions had to be found. On 
the linguistic level, translating the medical terms present in the original proved chal-
lenging, as it was necessary to identify appropriate, non-technical idiomatic formula-
tions in the translations to facilitate comprehension. Examples of these and other 
challenges and their solutions will be described in the presentation. CONCLUSIONS: 
According to the method used, the 29 language versions of the MSIS-29 were concep-
tually equivalent and culturally relevant. The translations may now be used in inter-
national studies to measure the physical and psychological impact of multiple sclerosis 
on patients’ day-to-day lives and facilitate the comparison and pooling of data. 
However, psychometric evaluation is required to determine stability of measurement 
performance across countries and cultures.
